Resverlogix Corp T.RVX

Alternate Symbol(s): RVXCF

Healthcare Biotechnology

Resverlogix Corp. is a Canada-based late-stage biotechnology company. The Company is engaged in epigenetics, with a focus on developing therapies for the benefit of patients with chronic diseases. Its epigenetic therapies are designed to regulate the expression of disease-causing genes. The Company's clinical program is focused on evaluating its lead candidate apabetalone (RVX-208) for the treatment of cardiovascular disease and associated comorbidities, and post-COVID-19 conditions. RVX-208 is a small molecule that is a selective bromodomain and extra-terminal (BET) inhibitor. BET bromodomain inhibition is an epigenetic mechanism that can regulate disease-causing genes. RVX-208 is a BET inhibitor selective for the second bromodomain (BD2) within the BET proteins. It partners with EVERSANA, to support the commercialization of RVX-208 for cardiovascular disease, post-COVID-19 conditions, and pulmonary arterial hypertension in Canada and the United States.

TSX:RVX - Post by User

Resverlogix Corp

Bullboard Posts

Comment by LifeGoesOn1973on Sep 25, 2019 12:23pm

140 Views

Post# 30163290

RE:volume & price action - the 2013 redux

the drop that started on June 4 was related to the spin out of Zenith that was announced on June 3 and the 10 M $ that RVX paid them to provide initial capitalization of Zenith. It was related to any leaked info related to the ASSURE results. as for BetonMace, I would like to refer you to the latest NR of the company on Sep 23 confirming that no one has access to the data, hence no leak

Bullboard Posts

3 Mid-Sized Stocks to Consider This Season